1338377-73-3

Basic information

• Product Name: (S)-1-cyclopropyl-2,2,2-trifluoroethan-1-amine hydrochloride
• Synonyms: (S)-1-cyclopropyl-2,2,2-trifluoroethan-1-amine hydrochloride
• CAS NO: 1338377-73-3
• Molecular Weight: 175.581
• Mol File: 1338377-73-3.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: (S)-1-cyclopropyl-2,2,2-trifluoroethan-1-amine hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-1-cyclopropyl-2,2,2-trifluoroethan-1-amine hydrochloride(1338377-73-3)
• EPA Substance Registry System: (S)-1-cyclopropyl-2,2,2-trifluoroethan-1-amine hydrochloride(1338377-73-3)

Safety Data

• Hazardous Substances Data: 1338377-73-3(Hazardous Substances Data)

Upstream product

• 1338377-51-7 N-[(1S)-1-cyclopropyl-2,2,2-trifluoroethyl]-(S)-2-methylpropane-2-sulfinamide 

Downstream Products

• 1616808-07-1 (S)-5-(N-(1-cyclopropyl-2,2,2-trifluoroethyl)sulfamoyl)-N-(3,4-difluorophenyl)-2-fluorobenzamide 
• 1416785-31-3 C₃₂H₃₇F₃N₈O₂Si 

Relevant articles and documents

THERAPEUTIC COMPOUNDS AND COMPOSITIONS

The present invention provides compounds that inhibit Factor XIa or kallikrein and pharmaceutically acceptable salts thereof and compositions thereof. The present invention also provides methods of using these compounds and compositions.

THERAPEUTIC COMPOUNDS AND COMPOSITIONS

The present invention provides compounds that inhibit Factor XIa or kallikrein and pharmaceutically acceptable salts thereof and compositions thereof. The present invention also provides methods of using these compounds and compositions.

Discovery of 1-amino-5 H-pyrido[4,3-b]indol-4-carboxamide inhibitors of janus kinase 2 (JAK2) for the treatment of myeloproliferative disorders

The JAK-STAT pathway mediates signaling by cytokines, which control survival, proliferation, and differentiation of a variety of cells. In recent years, a single point mutation (V617F) in the tyrosine kinase JAK2 was found to be present with a high incidence in myeloproliferative disorders (MPDs). This mutation led to hyperactivation of JAK2, cytokine-independent signaling, and subsequent activation of downstream signaling networks. The genetic, biological, and physiological evidence suggests that JAK2 inhibitors could be effective in treating MPDs. De novo design efforts of new scaffolds identified 1-amino-5H-pyrido[4,3-b]indol-4-carboxamides as a new viable lead series. Subsequent optimization of cell potency, metabolic stability, and off-target activities of the leads led to the discovery of 7-(2-aminopyrimidin-5-yl)-1- {[(1R)-1-cyclopropyl-2,2,2-trifluoroethyl]amino}-5H-pyrido[4,3-b] indole-4-carboxamide (65). Compound 65 is a potent, orally active inhibitor of JAK2 with excellent selectivity, PK profile, and in vivo efficacy in animal models.